Class IIOngoing

Lanreotide Injection recall

FDA recall D-0290-2026 · initiated Jan 2, 2026

May cause temporary or medically reversible harm; low probability of serious harm.

Why it was recalled

Presence of Particulate Matter.

Details

Product: Lanreotide Injection, 120 mg/0.5 mL, 0.5 mL per pre-filled syringe, For deep subcutaneous injection, Rx Only, Manufactured for: Cipla USA, Inc., 10 Independence Boulevard, Suite 300, Warren, NJ 07059. NDC: 69097-870-67
Recalling company: Cipla Limited
Classification: Class II
Status: Ongoing
Type: Voluntary: Firm initiated
Distribution: Nationwide in the USA
Initiated: Jan 2, 2026
FDA report date: Jan 21, 2026

What to do.If you have a recalled product, don't throw away questions — check the FDA notice for the affected lot numbers and expiration dates, and ask your pharmacist or doctor before stopping a prescribed medicine. This page reproduces public FDA data and is not medical advice.

Source: openFDA Drug Enforcement record D-0290-2026 ↗

← All drug recalls